The study conducted by Humanity & Health Medical Group Limited aims to assess the antibody response in chronic liver disease (CLD) patients to three different COVID-19 vaccines available in Hong Kong. Given the unique immune challenges faced by CLD patients, this research could provide critical insights into vaccine efficacy in this vulnerable population. The findings may influence vaccination strategies and guidelines, potentially leading to increased market demand for tailored vaccine solutions. Furthermore, the results could enhance the competitive positioning of the involved vaccine manufacturers (Pfizer-BioNTech, Sinovac, AstraZeneca) by demonstrating their products' effectiveness in a specific patient demographic. The completion of this study may also attract interest from healthcare providers and policymakers focused on improving vaccination outcomes in high-risk groups.